MedPath

SMA Motor Map - an extensive neurophysiologic protocol to assess (dys)function of the peripheral motor circuits in SMA

Recruiting
Conditions
Spinal Atrophy
Spinal Muscular Atrophy
10029299
Registration Number
NL-OMON49834
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
177
Inclusion Criteria

Part One:
• SMA type 1, 2, 3 and 4, confirmed with a homozygous or heterozygous deletion
of SMN1
• *12 years and older
• Treatment-naïve concerning SMN- modulators or NMJ-modulators (including
pyri-dostigmine and oral salbutamol)
o In case of the use of pyridostigmine by indication of SMA, patients are asked
to stop treatment 1 day prior to the examination

Part Two:
• SMA type 1, 2, 3 and 4, confirmed with a homozygous or heterozygous deletion
of SMN1
• *12 years and older
• Treatment with SMN- modulator

Exclusion Criteria

Strong apprehension against the performance of EMG of any kind

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Part 1<br /><br>CMAP (APB (median nerve))<br /><br>CMAP scan (APB (median nerve))<br /><br>Excitability testing (APB (median nerve))<br /><br>H-reflex (FCR (median nerve))<br /><br>RNS (3Hz at APB (median nerve) and trapezoid (n accesorius); 50Hz at APB<br /><br>(median nerve))<br /><br>SNAP (median/radial/ulnar nerve, sural nerve)<br /><br><br /><br>Part 2<br /><br>CMAP scan (APB (median nerve))<br /><br>SNAP (median nerve, sural nerve)<br /><br>Excitability testing (APB (median nerve))</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>n.a.</p><br>
© Copyright 2025. All Rights Reserved by MedPath